- Home
- PHAT vs CHW Comparison
PHAT vs CHW Comparison
Compare PHAT & CHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAT | CHW |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 590.6M | 527.5M |
| IPO Year | 2019 | 2007 |
Fundamental Metrics
Financial Performance| Metric | PHAT | CHW |
|---|---|---|
| Price | $7.15 | $7.76 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $20.09 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 217.9K |
| Earning Date | 10-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $80.58 | N/A |
| Revenue Next Year | $56.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $6.52 | $6.98 |
| 52 Week High | $18.31 | $9.18 |
Technical Indicators
Market Signals| Indicator | PHAT | CHW |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 33.36 |
| Support Level | $6.72 | $7.65 |
| Resistance Level | $7.72 | $8.26 |
| Average True Range (ATR) | 0.40 | 0.14 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 48.75 | 10.09 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities, and alternative investments.